Citations

Clear

623 citation(s) found for "Torres, V".

Development and Validation of the Orthostatic Tremor Severity and Disability Scale (OT‐10)
Merola, Aristide , Torres‐Russotto, Diego , Stebbins, Glenn T. , Vizcarra, Joaquín A. , Shukla, Aparna Wagle, Hassan, Anhar , Elble, Rodger J. , Deuschl, Günther , Deuschl, Günther , Espay, Alberto J , Shukla, Aparna Wagle , Marsili, Luca , Krauss, Joachim Kurt , Espay, Alberto J.

Mayo Clinic

Movement Disorders | June 20, 2020 | Volume: 35 | Issue: 10 | Pages: 1796-1801

10.1002/mds.28142 | PMID 32562441 Get It

AbstractBackgroundLimited tools are available for the assessment of orthostatic tremor severity and disability.ObjectivesTo develop and validate a self‐administered orthostatic tremor scale.MethodsAfter expert consensus and literature review generating a list of 42 items, the scale was developed and modified for validation after a patient focus group, multiple rounds of Delphi panels, and cognitive interviews. Clinimetric evaluations included assessing content validity, internal consistency, measurement error and reliability, construct validity, and concurrent validity anchored on the examiner's Clinical Global Impression score.ResultsEleven items ranked on a Likert scale from 0 (no disability/severity) to 5 (maximal disability/severity) were evaluated in 54 orthostatic tremor patients (16 men and 38 women; mean age: 69.17 ± 9.64 years; disease duration: 13.83 ± 11.24 years) to probe severity and disability over the preceding 1‐week period. The 11‐item scale showed good internal consistency (Cronbach's alpha = 0.863) and acceptable (>0.40) item‐to‐total correlation. However, one item was removed at the final Delphi panel because of significant floor effect, poor item‐to‐total correlation, and poor factor‐loading, leaving the scale with 10 items (10‐item Orthostatic Tremor Severity and Disability Scale). Test‐retest reliability at 2 weeks was excellent (two‐way random intraclass correlation coefficient > 0.90), and the individual item test‐retest reliability showed good agreement, with a threshold weighted kappa >0.60 for all items. Exploratory factor analyses revealed a parsimonious two‐factor construct accounting for 57.7% of the scale's variance. The 10‐item Orthostatic Tremor Severity and Disability Scale scores correlated with the CGI.ConclusionsThe self‐administered 10‐item Orthostatic Tremor Severity and Disability Scale scale is valid and reliable for capturing orthostatic tremor–related severity and disability. © 2020 International Parkinson and Movement Disorder Society
P0680A POST-HOC ANALYSIS OF EFFICACY AND SAFETY OF TOLVAPTAN (TOL) IN DECREASING RATE OF RENAL FUNCTION DECLINE IN PATIENTS WITH VERY LATE-STAGE AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Torres, Vicente, Gansevoort, Ronald T., Perrone, R. D., Chapman, Arlene B., Ouyang, John , Lee, Jennifer , Japes, Hina, Wang, Tao

Mayo Clinic

Nephrology Dialysis Transplantation | June 6, 2020 | Volume: 35 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfaa142.p0680 Get It

Abstract Background and Aims ADPKD is a progressive inherited disease that causes end-stage renal disease (ESRD) in ∼50% of the affected individuals by 60 years of age. TOL, a selective vasopressin V2-receptor antagonist, has been shown in randomized, placebo-controlled trials to slow the progression of renal function decline in ADPKD subjects with an eGFR of 25 mL/min/1.73m2 or higher. The efficacy and safety of TOL in subjects with lower eGFR remain understudied. This post-hoc analysis evaluated the efficacy and safety of TOL in subjects with stage 4 ADPKD (eGFR of <30 mL/min/1.73m2). Method This is a retrospective analysis of a subgroup of ADPKD subjects who enrolled in the TOL long-term open-label extension (OLE) trial (NCT02251275). Included subjects had a baseline eGFR of <30 mL/min/1.73m2, received ≥ 1 TOL dose, and were randomized to the placebo group in the REPRISE trial (NCT02160145). Two subgroups of subjects were analyzed, one with baseline eGFR of 25-30 (Subgroup 1) and one with <25 (Subgroup 2). The variables evaluated included: 1) demographics, 2) adverse event (AE) profile, 3) intra-subject comparison of change in annualized eGFR decline during the open-label study (treatment period) to that during placebo use in the REPRISE trial (control period). Annualized eGFR change slopes in the treatment period were calculated using eGFR values between Month 1 and 12 visits to compensate for the acute hemodynamic effect of tolvaptan. Comparison was made by linear mixed model. Results Of the 1,803 subjects enrolled, 159 (8.8%) subjects (76 in Subgroup 1 and 83 in Subgroup 2) met the selection criteria for analysis. Annualized eGFR change slopes for all subjects (n=148) were -5.28 (SE 0.27) in the control period and -3.16 (SE 0.30) in the treatment period with a treatment effect of 2.11 mL/min/1.73m2/year (95% CI 1.56, 2.66), p<0.0001). Demographic information, baseline eGFR, treatment duration and effects in the 2 subgroups are shown in the Table below. Treatment-emergent AEs were observed in 95% and 90% of the subjects in the 2 subgroups, respectively. Discontinuation due to AEs occurred in 15% and 17% of the 2 subgroups, respectively. The 5 most common AEs for all subjects were thirst (32%), polyuria (30%), renal pain (25%), blood creatinine increase (23%) and nocturia (22%); the rates were similar between the 2 subgroups. One incidence of hepatic enzyme increase, hemodialysis and death (unrelated to TOL) was observed in Subgroup 2, but not in Subgroup 1. Conclusion This post-hoc analysis demonstrated that TOL significantly decreases the rate of eGFR decline in ADPKD subjects with stage 4 CKD, including those with an eGFR of <25 mL/min/1.73m2.
Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease
Bae, Kyongtae T., Shi, Tiange , Tao, Cheng , Yu, Alan S.L. , Torres, Vicente E. , Perrone, Ronald D. , Chapman, Arlene B., Brosnahan, Godela , Steinman, Theodore I., Braun, William E. , Srivastava, Avantika , Irazabal, María V. , Harris, Peter C. , Landsittel, Douglas , Hogan, Marie C. , Abebe, Kaleab Z , Harris, Peter C , Torres, Vicente E , Yu, Alan S L , Torres, Vicente E , Irazabal, Maria V , Hogan, Marie C

Mayo Clinic

Journal of the American Society of Nephrology | June 2, 2020 | Volume: 31 | Issue: 7 | Pages: 1640-1651

10.1681/asn.2019101121 | PMID 32487558 Get It

Significance Statement Accurate prediction of risk for disease progression is crucial for clinical management of autosomal dominant polycystic kidney disease (ADPKD). The Mayo imaging classification of ADPKD uses height-adjusted total kidney volume (htTKV) and age to identify patients at highest risk. Because the current Mayo classification applies only to patients with typical diffuse cystic disease (class 1) and poorly predicts eGFR decline for the remaining 5%–10% of patients with atypical morphology (class 2), imaging-based risk modeling remains unresolved. The authors report an expanded imaging classification model in which use of a recalculated htTKV value that excludes prominent exophytic cysts improved prediction for eGFR trajectory. Using a recalculated htTKV may allow inclusion of class 2 patients in the Mayo classification of ADPKD and reclassification of class 1 patients with prominent exophytic cysts. Background The Mayo Clinic imaging classification of autosomal dominant polycystic kidney disease (ADPKD) uses height-adjusted total kidney volume (htTKV) and age to identify patients at highest risk for disease progression. However, this classification applies only to patients with typical diffuse cystic disease (class 1). Because htTKV poorly predicts eGFR decline for the 5%–10% of patients with atypical morphology (class 2), imaging-based risk modeling remains unresolved. Methods Of 558 adults with ADPKD in the HALT-A study, we identified 25 patients of class 2A with prominent exophytic cysts (class 2Ae) and 43 patients of class 1 with prominent exophytic cysts; we recalculated their htTKVs to exclude exophytic cysts. Using original and recalculated htTKVs in association with imaging classification in logistic and mixed linear models, we compared predictions for developing CKD stage 3 and for eGFR trajectory. Results Using recalculated htTKVs increased specificity for developing CKD stage 3 in all participants from 82.6% to 84.2% after adjustment for baseline age, eGFR, BMI, sex, and race. The predicted proportion of class 2Ae patients developing CKD stage 3 using a cutoff of 0.5 for predicting case status was better calibrated to the observed value of 13.0% with recalculated htTKVs (45.5%) versus original htTKVs (63.6%). Using recalculated htTKVs reduced the mean paired difference between predicted and observed eGFR from 17.6 (using original htTKVs) to 4.0 ml/min per 1.73 m 2 for class 2Ae, and from −1.7 (using original htTKVs) to 0.1 ml/min per 1.73 m 2 for class 1. Conclusions Use of a recalculated htTKV measure that excludes prominent exophytic cysts facilitates inclusion of class 2 patients and reclassification of class 1 patients in the Mayo classification model.
Reactive Oxygen Species and Redox Signaling in Chronic Kidney Disease
Irazabal, María V. , Irazabal, Maria V , Torres, Vicente E.

Mayo Clinic

Cells | May 29, 2020 | Volume: 9 | Issue: 6 | Pages: 1342

10.3390/cells9061342 | PMID 32481548 Get It

Chronic kidney disease (CKD) remains a worldwide public health problem associated with serious complications and increased mortality rates. Accumulating evidence indicates that elevated intracellular levels of reactive oxygen species (ROS) play a major role in the pathogenesis of CKD. Increased intracellular levels of ROS can lead to oxidation of lipids, DNA, and proteins, contributing to cellular damage. On the other hand, ROS are also important secondary messengers in cellular signaling. Consequently, normal kidney cell function relies on the “right” amount of ROS. Mitochondria and NADPH oxidases represent major sources of ROS in the kidney, but renal antioxidant systems, such as superoxide dismutase, catalase, or glutathione peroxidase counterbalance ROS-mediated injury. This review discusses the main sources of ROS and antioxidant systems in the kidney, and redox signaling pathways leading to inflammation and fibrosis, which result in abnormal kidney function and CKD progression. We further discuss the important role of the nuclear factor erythroid 2-related factor 2 (Nrf2) in regulating antioxidant responses, and other mechanisms of redox signaling.
A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).
Weigelt, Britta , Rexer, Brent N. , Forero‐Torres, Andres , Nanda, Rita , Storniolo, Anna Maria , Krop, Ian E. , Osborne, C. Kent , Veeraraghavan, Jamunarani , Gutiérrez, Carolina , Angelis, Carmine De , Wang, Tao , Pascual, Tomás , Galvan, Patricia , Wolff, Antonio C. , Goetz, Matthew P. , Reis‐Filho, Jorge S. , Hilsenbeck, Susan Galloway , Prat, Aleix , Schiff, Rachel , Rimawi, Mothaffar F.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 1011-1011

10.1200/jco.2020.38.15_suppl.1011 Get It

1011 Background: Several trials have shown 25-30% pathologic complete response (pCR) rates in patients with HER2+ BC treated with LT therapy (+ endocrine therapy if ER+), but no chemotherapy (CTX). We hypothesize that a multiparameter classifier, comprised of HER2 gene and protein levels, intratumor heterogeneity (ITH), HER2-enriched (E) subtype, and PIK3CA mutation status can identify patients whose tumors are “addicted” to HER2 signaling and are likely to achieve pCR from a CTX-sparing de-escalation strategy. Methods: Baseline specimens from 2 trials (TBCRC023 [NCT00999804] and PAMELA [NCT01973660]) of neoadjuvant CTX-sparing LT (+ endocrine therapy if ER+) in HER2+ BC were used. HER2 protein and ITH (scored for % 3+ by IHC), and gene amplification (HER2:CEP17 ratio and copy number (CN) by CISH) were measured on the same slide by the dual gene protein assay (GPA). HER2-E and PIK3CA mutation status were assessed by research-based PAM50 and MSK-IMPACT platforms, respectively. A decision tree algorithm was used to determine the GPA cutoffs and to construct the classifier of response (by pCR) in TBCRC023, which was then validated in PAMELA. Results: Of the evaluable patients from TBCRC023 (N = 130) and PAMELA (N = 151), GPA data were available for 121 and 94 cases, respectively. Both cohorts exhibited similar distributions for HER2 ratio, CN, and % 3+, and a strong correlation between HER2 ratio and CN (R > 0.92). In TBCRC023, 73 cases had data from GPA, PAM50, and IMPACT, of which 15 had pCR. Recursive partitioning identified cutoffs of HER2 ratio > 4.6 and % 3+ > 97.5% in both the GPA data cohort (N = 121) and complete data cohort (N = 73). With PAM50 and IMPACT data, the model added HER2-E and PIK3CA wild-type (wt). For practical reasons, the classifier was locked as HER2 ratio ≥ 4.5 AND % 3+ ≥ 90% AND PIK3CA-wt AND HER2-E, which yielded a PPV of 55% and NPV of 94%. Validation in PAMELA using 45 cases with data for all 3 assays yielded PPV of 44% and NPV of 82%. 29 TBCRC023 cases without IMPACT data could be predicted to be non-pCR, of which 26 were correct (NPV = 89%). In PAMELA, 66 additional cases could be predicted to be non-pCR, of which 54 were correct (NPV = 81%). Conclusions: We have constructed a multiparameter classifier that can predict pCR with targeted therapy alone that compare to pCR rates of CTX + dual anti-HER2 in unselected patients. Prospective validation in a clinical trial is warranted. [Table: see text]
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease
Grau, Laura , McNair, Bryan , Harris, Peter C. , Brosnahan, Godela , Torres, Vicente E. , Steinman, Theodore I., Yu, Alan S.L. , Chapman, Arlene B., Chonchol, Michel , Nowak, Kristen L. , Nowak, Kristen L , Harris, Peter C , Torres, Vicente E , Yu, Alan S L , Gitomer, Berenice Y , Wolf, Myles Selig

Mayo Clinic

Kidney360 | May 12, 2020 | Volume: 1 | Issue: 7 | Pages: 648-656

10.34067/kid.0001692020 | PMID 33305291 Get It

Background Higher serum intact fibroblast growth factor 23 (iFGF23) was associated with disease progression in participants with autosomal dominant polycystic kidney disease (ADPKD) in the HALT-PKD Studies. PKD mutation is also an important determinant of progression. We hypothesized that serum levels of iFGF23 and vitamin D metabolites (1,25-dihydroxyvitamin D [1,25(OH) 2 D] and 25-hydroxyvitamin D [25[OH]D]) differ according to ADPKD mutation and differentially predict clinical end points according to genotype (significant interaction between genotype and mineral metabolites). Methods A total of 864 individuals with ADPKD who participated in the HALT-PKD Study A or B and had measurements of mineral metabolites (1,25[OH] 2 D, 25[OH]D, iFGF23) were categorized by PKD mutation (PKD1 truncating, PKD1 nontruncating, PKD2, or no mutation detected [NMD]). The association of the interactions of genotype × iFGF23, genotype × 1,25(OH)2D, and genotype × 25(OH)D with ( 1 ) annualized change in eGFR; ( 2 ) mean annualized percentage change in height-corrected total kidney volume (Study A only); and ( 3 ) time to a composite of 50% reduction in eGFR, ESKD, or death were evaluated using linear regression and Cox proportional hazards regression. Results Median (interquartile range) iFGF23 differed (PKD1 truncating, 55.8 [40.7–76.8]; PKD1 nontruncating, 49.9 [37.7–71.0]; PKD2, 49.0 [33.8–70.5]; NMD, 50.3 [39.7–67.4] pg/ml; P =0.03) and mean±SD 1,25(OH) 2 D differed (PKD1 truncating, 32.8±12.8; PKD1 nontruncating, 33.4±12.5; PKD2, 34.1±13.1; NMD, 38.0±14.6 pg/ml; P =0.02) according to PKD genotype. There was a significant interaction between iFGF23 and genotype ( P =0.02) for the composite end point in fully adjusted models, but no significant interaction between 1,25(OH) 2 D or 25(OH)D and genotype for clinical end points. Conclusions ADPKD genotype interacts significantly with FGF23 to influence clinical end points. Whereas the worst outcomes were in individuals with a PKD1-truncating or -nontruncating mutation and the highest iFGF23 tertile, risk of the composite end point differed according to iFGF23 the most in the PKD1-nontruncating and PKD2 groups.
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
Mehta–Shah, Neha , Ansell, Stephen M. , Barnes, Jeffrey A. , Clemens, Mark W. , Fisher, Kristopher , Goodman, Aaron M. , Guitart, Joan , Halwani, Ahmad , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Lunning, Matthew A. , Olsen, Elise A. , Pro, Barbara, Rajguru, Saurabh, Shaver, Aaron C., Shustov, Andrei R., Sokol, Lubomir , Torka, Pallawi , Torres‐Cabala, Carlos A. , William, Basem M. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, William, Basem , Torres-Cabala, Carlos , Hoppe, Richard T , Horwitz, Sarah McCue , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Goyal, Gaurav , Mehta, Amitkumar , Shanbhag, Satish , Sokol, Lubomir , Wilcox, Ryan A. , Kim, Youn H

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 7, 2020 | Volume: 18 | Issue: 5 | Pages: 522-536

10.6004/jnccn.2020.0022 | PMID 32380458 Get It

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).
Approximations to the Voice of a Cochlear Implant: Explorations With Single-Sided Deaf Listeners
Dorman, Michael F. , Natale, Sarah Cook, Baxter, Leslie C. , Zeitler, Daniel M. , Carlson, Matthew L. , Lorens, Artur , Skarżyńśki, Henryk , Peters, Jeroen P. M. , Torres, Jennifer H., Noble, Jack H. , Baxter, Leslie C.

Mayo Clinic

Trends in Hearing | April 27, 2020 | Volume: 24 | Issue: No issue available | Pages: No page available

10.1177/2331216520920079 | PMID 32339072 Get It

Fourteen single-sided deaf listeners fit with an MED-EL cochlear implant (CI) judged the similarity of clean signals presented to their CI and modified signals presented to their normal-hearing ear. The signals to the normal-hearing ear were created by (a) filtering, (b) spectral smearing, (c) changing overall fundamental frequency (F0), (d) F0 contour flattening, (e) changing formant frequencies, (f) altering resonances and ring times to create a metallic sound quality, (g) using a noise vocoder, or (h) using a sine vocoder. The operations could be used singly or in any combination. On a scale of 1 to 10 where 10 was a complete match to the sound of the CI, the mean match score was 8.8. Over half of the matches were 9.0 or higher. The most common alterations to a clean signal were band-pass or low-pass filtering, spectral peak smearing, and F0 contour flattening. On average, 3.4 operations were used to create a match. Upshifts in formant frequencies were implemented most often for electrode insertion angles less than approximately 500°. A relatively small set of operations can produce signals that approximate the sound of the MED-EL CI. There are large individual differences in the combination of operations needed. The sound files in Supplemental Material approximate the sound of the MED-EL CI for patients fit with 28-mm electrode arrays.
Recent Advances and Clinical Outcomes of Kidney Transplantation
Hansrivijit, Panupong , Leeaphorn, Napat , Acharya, Prakrati , Torres‐Ortiz, Aldo, Kaewput, Wisit , Kovvuru, Karthik , Kanduri, Swetha Rani , Cheungpasitporn, Wisit , Kaewput, Wisit , Cheungpasitporn, Wisit , Hansrivijit, Panupong , Thongprayoon, Charat

Mayo Clinic

Journal of Clinical Medicine | April 23, 2020 | Volume: 9 | Issue: 4 | Pages: 1193

10.3390/jcm9041193 | PMID 32331309 Get It

Recent advances in surgical, immunosuppressive and monitoring protocols have led to the significant improvement of overall one-year kidney allograft outcomes. Nonetheless, there has not been a significant change in long-term kidney allograft outcomes. In fact, chronic and acute antibody-mediated rejection (ABMR) and non-immunological complications following kidney transplantation, including multiple incidences of primary kidney disease, as well as complications such as cardiovascular diseases, infections, and malignancy are the major factors that have contributed to the failure of kidney allografts. The use of molecular techniques to enhance histological diagnostics and noninvasive surveillance are what the latest studies in the field of clinical kidney transplant seem to mainly focus upon. Increasingly innovative approaches are being used to discover immunosuppressive methods to overcome critical sensitization, prevent the development of anti-human leukocyte antigen (HLA) antibodies, treat chronic active ABMR, and reduce non-immunological complications following kidney transplantation, such as the recurrence of primary kidney disease and other complications, such as cardiovascular diseases, infections, and malignancy. In the present era of utilizing electronic health records (EHRs), it is strongly believed that big data and artificial intelligence will reshape the research done on kidney transplantation in the near future. In addition, the utilization of telemedicine is increasing, providing benefits such as reaching out to kidney transplant patients in remote areas and helping to make scarce healthcare resources more accessible for kidney transplantation. In this article, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored.
Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics
Wang, Sa A. , Wolniak, Kristy , Psarra, Katherina , Illingworth, Andrea , Johansson, Ulrika , Craig, Fiona E. , Torres, Richard , Horna, Pedro , Craig, Fiona E , Almeida, Júlia

Mayo Clinic

Cytometry Part B: Clinical Cytometry | April 22, 2020 | Volume: 100 | Issue: 2 | Pages: 142-155

10.1002/cyto.b.21878 | PMID 32319723 Get It

AbstractA peripheral blood flow cytometric assay for Sézary syndrome (SS) or circulating mycosis fungoides (MF) cells must be able to reliably identify, characterize, and enumerate T‐cells with an immunophenotype that differs from non‐neoplastic T‐cells. Although it is also important to distinguish SS and MF from other subtypes of T‐cell neoplasm, this usually requires information in addition to the immunophenotype, such as clinical and morphologic features. This article outlines the approach recommended by an international group with experience and expertise in this area. The following key points are discussed: (a) At a minimum, a flow cytometric assay for SS and MF should include the following six antibodies: CD3, CD4, CD7, CD8, CD26, and CD45. (b) An analysis template must reliably detect abnormal T‐cells, even when they lack staining for CD3 or CD45, or demonstrate a phenotype that is not characteristic of normal T‐cells. (c) Gating strategies to identify abnormal T‐cells should be based on the identification of subsets with distinctly homogenous immunophenotypic properties that are different from those expected for normal T‐cells. (d) The blood concentration of abnormal cells, based on any immunophenotypic abnormalities indicative of MF or SS, should be calculated by either direct enumeration or a dual‐platform method, and reported.